Scientific article
French

Antiplaquettaires et patients âgés : quelles molécules et quelles preuves ?

Published in

Revue médicale suisse, vol. 9, no. 405, p. 2034-2038

Publication date

2013

Abstract

Antiplatelet drugs are a cornerstone for the management of all atherosclerosis-related conditions, increasingly frequent with advanced age. Associations of antiplatelet drugs increase the bleeding risk and the overall net clinical benefit should be carefully assessed. In the absence of recommendations made specifically for the elderly practical suggestions can be inferred from subgroup analyses of large trials. The association of two antiplatelet agents should be limited to acute coronary syndromes for a maximum of one year, avoiding prasugrel in 75 years and older patients, and to coronary angioplasties for a minimum duration depending on the type of stent. In elderly patients with atrial fibrillation and ischemic heart disease more than one year after coronary stenting, a vitamin K antagonist alone is usually sufficient.

Citation (ISO format)

RENY, Jean-Luc, ROFFI, Marco, FONTANA, Pierre. Antiplaquettaires et patients âgés : quelles molécules et quelles preuves ? In: Revue médicale suisse, 2013, vol. 9, n° 405, p. 2034–2038.

Main files (1)

Article (Published version)

Identifiers

Additional URL for this publication

http://rms.medhyg.ch/numero-405-page-2034.htm

Journal ISSN

1660-9379
604views
0downloads

Technical informations

Creation

16/12/2013 09:33:00

First validation

16/12/2013 09:33:00

Update

13/10/2025 23:03:15

Status update

03/02/2025 11:33:42

Last indexation

28/09/2026 12:17:04
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated